Guha et al. also evaluated the role of the specific blockade of CCN2 with a CCN2 ASO of novel chimeric chemistry (phosphorothioate and phosphodiester) in the progression of DN with a convenient biweekly dose schedule. The gene discussed is CCN2; the disease is liver dysplastic nodule.